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OBJECTIVES We prospectively compared dipyridamole single-photon emission computed tomography
(SPECT) imaging with Tc-99m sestamibi and Tc-99m tetrofosmin for the detection of
reversible perfusion defects in patients with mild-to-moderate coronary artery disease.
BACKGROUND Tc-99m tetrofosmin has a lower first-pass myocardial extraction fraction compared to
Tc-99m sestamibi and thus could underestimate mild perfusion defects.
METHODS Eighty-one patients with 50% to 90% stenosis in one or two major epicardial vessels without
previous myocardial infarction, and seven with ,5% probability of coronary artery disease
underwent dipyridamole SPECT imaging with both agents. The SPECT data were analyzed
quantitatively.
RESULTS Tc-99m sestamibi detected reversible perfusion defects in a greater number of segments (total
363 and 285, p , 0.001, and mean 6 SD, 2.2 6 3.0 and 1.8 6 2.5 per patient, p 5 0.008,
for Tc-99m sestamibi and Tc-99m tetrofosmin, respectively), demonstrated a larger extent of
perfusion defect (mean 6 SD, 15.8% 6 12.3% and 12.0% 6 11.4%, p , 0.03, for Tc-99m
sestamibi and Tc-99m tetrofosmin, respectively) and more often correctly identified patients
with disease in more than one coronary artery (p 5 0.02). There was better defect contrast
with Tc-99m sestamibi (defect/normal wall count ratios were 0.60 6 0.15 vs. 0.73 6 0.14 for
Tc-99m sestamibi and Tc99m tetrofosmin, respectively, p 5 0.01, for reversible defects seen
in identical segments with both agents; and 0.73 6 0.16 vs 0.79 6 0.17, respectively, p ,0.01,
for reversible defects detected with either agent alone). There was no significant difference in
diagnostic sensitivity or image quality.
CONCLUSIONS These differences between two commonly used tracers may have significant diagnostic and
prognostic implications. (J Am Coll Cardiol 2001;37:458–62) © 2001 by the American
College of Cardiology
Tc-99m sestamibi and Tc-99m tetrofosmin have similar
physical properties that offer significant advantages over
thallium-201 for gamma camera imaging (1–3). However,
the myocardial extraction fraction of Tc-99m tetrofosmin is
lower than that of Tc-99m sestamibi, and there is a
relatively earlier “roll off” in the linear relationship between
tracer uptake and myocardial blood flow for Tc-99m tetro-
fosmin (4), which could result in underestimation of perfu-
sion abnormalities (5). Although two recent comparative
studies of these two agents suggested diagnostic equivalence
(6,7), they have never been compared specifically using
vasodilator stress testing in patients with mild coronary
disease, conditions in which the effects of a low myocardial
extraction fraction are most likely to manifest (4,5,8,9).
Therefore, this study was designed to compare the
diagnostic accuracy of Tc-99m sestamibi and Tc-99m
tetrofosmin single-photon emission computed tomography
(SPECT) for the detection of reversible perfusion abnor-
malities induced by dipyridamole stress in patients with
mild-to-moderate coronary artery disease (CAD).
METHODS
Patient selection. Patients with mild-to-moderate stable
CAD, defined as 50% to 90% stenosis in one or two major
epicardial coronary arteries on recent (,2 months) qualita-
tive coronary arteriography, who consented to participate,
were prospectively enrolled. In addition, patients with a low
likelihood (,5% pretest probability) (10) of CAD were also
included to eliminate reporting bias. Exclusion criteria
included severe coronary disease (left main stem disease,
.90% stenosis in any artery, three-vessel disease), previous
myocardial infarction, significant valvular disease, left bun-
dle branch block and clinically unstable CAD. Standard
exclusion criteria for dipyridamole stress were applied (11).
Study design. The protocol was approved by the Institu-
tional Review Boards of both institutions. After informed
consent, all patients underwent dipyridamole stress SPECT
imaging with Tc-99m sestamibi and Tc-99m tetrofosmin in
random order within two weeks of each other. A two-day
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(U.K.) or same-day (Canada) rest-stress protocol was used
(12), with individual patients subjected to the same protocol
for imaging with both agents. Perfusion imaging was
performed within two months of coronary arteriography.
Dipyridamole stress. The standard high-dose dipyrida-
mole protocol (0.56 mg/kg, followed by 0.28mg/kg in the
absence of adverse effects) was used (13). In any given
patient the same dose of dipyridamole was used for imaging
with both agents, and the tracer was injected 2 to 3 min after
the completion of the infusion.
SPECT imaging. For the two-day stress rest protocol,
16 mCi of tracer was injected on each occasion. In the
one-day protocol rest images were initially performed with
10 mCi of tracer followed 4 h later by the stress study with
30 mCi of tracer. SPECT imaging was performed 60 min
after tracer injection with a large field-of-view, dual-headed
gamma camera equipped with a high-resolution collimator
using methods previously described (14).
IMAGE ANALYSIS. The SPECT images were analyzed by
two independent experts (EGD, JEU) blinded to the
patient’s clinical details and tracer identity. The Tc-99m
sestamibi and Tc-99m tetrofosmin scans of any given
patient were read randomly. The left ventricle was divided
into 17 segments on three short axes and one vertical long
axis slices, and each segment was graded according to
perfusion using a semiquantitative four-point system (1 5
normal, 2 5 mildly reduced, 3 5 severely reduced, 4 5
absent), and classified as normal, reversible (new or wors-
ening stress defect) or fixed (identical stress and rest
defects). The overall image quality was assigned one of four
grades (excellent, good, fair, poor) based on count density,
myocardial and left ventricular cavity definition and adjacent
interfering visceral activity.
QUANTITATIVE ANALYSIS. The extent of defect was quan-
tified using CEqual software (15) as a percentage of the
entire myocardium involved. The defect/normal wall activ-
ity ratio was used to calculate the severity of the defect and
was determined in two groups of patients: those in whom
reversible perfusion defects in identical segments were
detected by both Tc-99m sestamibi and Tc-99m tetrofos-
min, and those in whom reversible defects were detected by
one agent only. For this analysis, we summed four short axis
slices, taking care to choose identical slices from Tc-99m
sestamibi and Tc-99m tetrofosmin images of any given
patient. Regions of interest were then placed manually on
the area of defect and the area of the myocardium with the
maximum tracer uptake, with the operator blinded to the
tracer identity. By determining the count densities within
the defect and normal regions of interest for each defect, a
mean defect/normal count density ratio was computed. The
average of three values was taken.
STATISTICAL ANALYSIS. Sensitivity and specificity were de-
termined using standard formulae and compared using the
McNemar test. The concordance between tetrofosmin and
sestamibi for classifying scans (overall and segmental) into
normal, reversible and fixed categories and for overall image
quality was determined with kappa statistics. The difference
in the average number of reversible segments detected per
patient was compared using the paired t test. Comparison
of the two agents for diagnostic categorization was per-
formed using the Stuart–Maxwell test (16) of marginal
homogeneity (paired comparison of the row totals with the
column totals, to see whether the two agents classify the
same proportion of patients into the three categories) and
Bowker’s test for symmetry (17) (a comparison of the
symmetry of individual cells about the table diagonal), and
image quality was compared using the Wilcoxon signed
rank test. All data are expressed as mean 6 standard
deviation (SD). A p-value of ,0.05 was considered signif-
icant.
RESULTS
Eighty-eight patients (63 men, 25 women) were included in
the study. The mean age was 59.7 6 12 years and mean
weight 76.2 6 15.4 kg. Fifty-eight and 30 patients were
recruited at the U.K. and Canadian sites, respectively; 40
had the Tc-99m tetrofosmin scan performed first.
Coronary anatomy. Eighty-one patients had 50% to 90%
stenosis in one or two major epicardial coronary arteries; 52
had single and 29 two-vessel disease. One patient had
normal coronary arteries and six patients were not subjected
to arteriography because of ,5% pretest likelihood of
coronary disease.
Hemodynamics during stress testing. There were no
significant differences in hemodynamic parameters during
stress testing with Tc-99m sestamibi and Tc-99m tetrofos-
min (p 5 NS for rest and peak heart rate and blood
pressure).
Detection of reversible perfusion defects. Tc-99m sesta-
mibi demonstrated reversible perfusion defects in a signifi-
cantly greater number of myocardial segments (363 and 285
reversible segments by Tc-99m sestamibi and Tc-99m
tetrofosmin, respectively, p , 0.0001, Table 1). Additional
Abbreviations and Acronyms
CAD 5 coronary artery disease
SPECT5 single-photon emission computed tomography
Table 1. Ischemic Burden Demonstrated by Tc-99m Sestamibi
(MIBI) and Tc-99m Tetrofosmin (TETRO) in Mild to
Moderate Coronary Artery Disease
MIBI TETRO p Value
Reversible segments 363 285 , 0.0001
Defect extent
(%LV involved)
15.8 6 12.3% 12 6 11.9% , 0.03
Defect severity
(defect/normal
wall count ratio)
0.60 6 0.15 0.73 6 0.14 0.01
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analysis of the U.K. subgroup showed that the average
number of reversible segments detected per patient was
2.2 6 3.0 and 1.8 6 2.5 for Tc-99m sestamibi and Tc-99m
tetrofosmin, respectively (p 5 0.008, 95% CI for the
difference 0.12–0.78). However, even though Tc-99m ses-
tamibi demonstrated reversible perfusion defects in 50
patients compared with 45 by tetrofosmin, this difference
did not achieve statistical significance.
Extent and severity of perfusion defects. The extent of
perfusion abnormality demonstrated by Tc-99m sestamibi
was also significantly greater compared with Tc-99m tetro-
fosmin (15.8 6 12.3% and 12.0 6 11.4%, respectively, p ,
0.01). In patients in whom both Tc-99m sestamibi and
Tc-99m tetrofosmin studies showed reversible perfusion
defects in identical segments, the defect/normal wall ratio
was 0.60 6 0.15 for Tc-99m sestamibi and 0.73 6 0.14 for
Tc-99m tetrofosmin (p 5 0.01). In patients where revers-
ible perfusion defects were not detected concordantly by
both agents, the defect/normal wall ratio was 0.73 6 0.16
for Tc-99m sestamibi and 0.79 6 0.17 for Tc-99m tetro-
fosmin (p , 0.01, Table 2), indicating that Tc-99m
sestamibi demonstrated perfusion defects of greater severity.
Figures 1 and 2 show SPECT images from two patients
with CAD in whom Tc-99m sestamibi demonstrated
greater defect extent, severity and reversibility.
Concordance for categorization of defects. The overall
concordance between Tc-99m sestamibi and Tc-99m tet-
rofosmin for categorizing normal, fixed and reversible scans
was 78% (69/88, kappa 5 0.60). Among patients with
angiographic coronary disease, ten scans were positive by
Tc-99m sestamibi (nine reversible, one fixed) and normal by
Tc-99m tetrofosmin. In contrast, six scans were abnormal
by Tc-99m tetrofosmin (five reversible, one fixed) and
normal by Tc-99m sestamibi; of these, only four patients
had angiographic coronary disease and two scans were false
positive (p 5 NS).
On a segmental basis, the concordance for similar cate-
gorization was 86% (1,291/1,496, kappa 5 0.67). Of 119
segments classified as normal by Tc-99m tetrofosmin,
Tc-99m sestamibi demonstrated reversible and fixed defects
in 101 and 18 segments, respectively. In contrast, there were
only 54 segments classified as normal by Tc-99m sestamibi
where Tc-99m tetrofosmin detected abnormalities (49 re-
versible, five fixed; p , 0.001 by both Stuart-Maxwell and
Bowker’s tests, Table 2).
Prediction of two-vessel disease. In the 29 patients with
two-vessel disease, Tc-99m sestamibi and Tc-99m tetrofos-
min identified perfusion defects in two vascular territories in
14 and seven patients, respectively (p 5 0.02, Fig. 3).
Patients with three-vessel disease were excluded from the
study.
Detection of CAD. The sensitivity of the two agents for
the detection of mild-to-moderate CAD was not signifi-
cantly different from each other (63% [51/81] for Tc-99m
sestamibi and 58% [47/81] for Tc-99m tetrofosmin, p 5
0.09). In the seven patients with ,5% probability of CAD
or with normal coronary arteries, the specificity of both
agents was 57.1%.
Table 2. Segmental Analysis of Perfusion Defects in Patients
With Mild-to-Moderate Coronary Artery Disease
TETRO
Normal Reversible Fixed
MIBI
Normal 1,011 49 5
Reversible 101 233 29
Fixed 18 3 47
Segmental agreement: 1,291/1,496 (86.3%) kappa 5 0.67. MIBI was superior for
detecting reversible defects (p , 0.0001).
MIBI 5 Tc-99m sestamibi; TETRO 5 Tc-99m tetrofosmin.
Figure 1. Representative horizontal and vertical long axes slices from the
Tc-99m tetrofosmin (TETRO) and Tc-99m sestamibi (MIBI) stress (S)
and rest (R) SPECT images of a 67-year-old female patient with a 50%
stenosis of her mid left anterior descending coronary artery and 90%
stenosis of the proximal left circumflex coronary artery. There are infero-
apical and lateral defects in the Tc-99m sestamibi scan while the Tc-99m
tetrofosmin scan is only mildly abnormal.
Figure 2. Representative horizontal and vertical long axes, and short axis
slices from the Tc-99m tetrofosmin (TETRO) and Tc-99m sestamibi
(MIBI) stress (S) and rest (R) SPECT images of a 64-year-old man with
90% stenosis of the proximal left anterior descending coronary artery. The
perfusion abnormality involving the apex, septum, and anterior walls is
more severe and extensive on the Tc-99m sestamibi scan.
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Image quality. There was overall agreement of 67%
(59/88) for classification of images based on quality into
excellent, good, fair and poor categories, p 5 NS (Table 3).
DISCUSSION
The results of this study indicate that in patients with mild-
to-moderate CAD, dipyridamole SPECT imaging with
Tc-99m sestamibi demonstrates greater perfusion defect
extent, severity and reversibility than does Tc-99m tetrofos-
min, and more accurately predicts disease in more than one
vessel. The low sensitivity of both agents demonstrated in
this study in comparison to previously published results
(18–21) was expected as a result of the deliberate selection
of patients with only mild-to-moderate coronary disease
without previous myocardial infarction. The lack of a
significant difference in the diagnostic sensitivity of the two
agents despite a trend in favor of Tc-99m sestamibi is most
likely a reflection of inadequate sample size. On the basis of
current results it is estimated that 135 and 541 patients
would be required to demonstrate a 10% and 5% difference
in diagnostic sensitivity, respectively (at 5% level of signif-
icance and 80% power).
Mechanism. The parallel relationship between myocardial
blood flow and the myocardial uptake of extractable flow
tracers is limited by the roll-off phenomenon, a plateau of
tracer uptake when myocardial blood flow is progressively
increased (4,9,22). The precise flow rate at which this phe-
nomenon occurs is determined by the first-pass myocardial
extraction of the tracer (4,9). Hence, the myocardial uptake of
Tc-99m teboroxime (Emax 0.63 to 0.81) (23), thallium-201
(Emax 0.59 to 0.73) (24), and Tc-99 sestamibi (Emax 0.31 to
0.73) (25) plateau at progressively lower blood flow rates of
5 ml/g/min, 3 ml/g/min and 2 ml/g/min, respectively (4,26).
Tc-99m tetrofosmin has a lower extraction fraction (Emax 0.15
to 0.33) and may plateau when myocardial blood flow increases
approximately 1.5-fold (5). The plateau effect limits the sen-
sitivity of a tracer to detect CAD and reversible perfusion
defects by reducing defect contrast (4,9). It may affect imaging
with vasodilator stress more than dynamic exercise (5,9), and
the detection of mild rather than severe coronary disease (8).
Accordingly, previous animal and clinical studies have dem-
onstrated greater underestimation of coronary flow heteroge-
neity (27) and stress perfusion defect size and extent by both
Tc-99m sestamibi and Tc-99m tetrofosmin compared with
thallium-201 (28–32). Two of these studies (29,30) reported a
similar defect extent on the rest Tc-99m sestamibi and redis-
tribution thallium-201 images, suggesting that the smaller
defect size on stress Tc-99m sestamibi imaging may have been
due to its lower myocardial extraction during exercise induced
vasodilation.
Previous studies. Two small intraindividual comparative
studies of Tc-99m sestamibi and Tc-99m tetrofosmin
showed diagnostic equivalence. However, Flamen et al. (6)
did not report on coronary anatomy, whereas Acampa and
colleagues (7) used dynamic exercise stress and patients with
severe disease (of 25 patients, 15 and 14 had previous
myocardial infarction and multivessel disease, respectively).
Therefore, differences occurring as a result of low tracer
extraction may not have manifested.
Implications for risk stratification. Although there is now
a large volume of data involving several thousand patients
establishing the prognostic utility of Tc-99m sestamibi
myocardial perfusion imaging (14, 33–36), in the light of
the current results this should not be empirically extrapo-
lated to Tc-99m tetrofosmin imaging when vasodilator
stress is used.
Limitations of the study. We were limited by the lack of a
quantification program validated for both agents. Although the
CEqual software to quantify perfusion defects has been vali-
dated for Tc-99m sestamibi but not for Tc-99m tetrofosmin,
at least two previous studies have suggested that the choice of
the quantitative program is unlikely to influence the imaging
results to any significant degree (37,38).
Conclusion. Dipyridamole SPECT imaging with Tc-99m
sestamibi demonstrates greater myocardial perfusion defect
reversibility, extent and severity than Tc-99m tetrofosmin in
patients with mild-to-moderate CAD, and is more likely to
correctly identify patients with disease in more than one
coronary artery. These findings may have significant diag-
nostic and prognostic implications.
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Figure 3. Detection of perfusion defects in two vascular territories in
the 29 patients with two-vessel coronary artery disease (p 5 0.02 by
McNemar’s test).
Table 3. Image Quality
TETRO
Poor Fair Good Excellent
MIBI
Poor — — — 1
Fair — 1 — 1
Good — 3 16 10
Excellent — 1 13 42
Agreement: 59/88 (67%); p 5 NS.
MIBI 5 Tc-99m sestamibi; TETRO 5 Tc-99m tetrofosmin.
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